Immune thrombocytopenia (ITP) is a heterogeneous disease caused by autoantibody‐mediated reaction of B cells and T cells to megakaryocytes leading to thrombocytopenia and life‐threatening bleeding (Cooper & Bussel, [2006](#bjh16161-bib-0013){ref-type="ref"}; Rodeghiero *et al*, [2009](#bjh16161-bib-0033){ref-type="ref"}). Patients who fail to respond to initial treatment within 3--12 months are diagnosed with persistent ITP (Rodeghiero *et al*, [2009](#bjh16161-bib-0033){ref-type="ref"}). These patients require second‐line medical treatment with or without splenectomy if they are at risk of bleeding due to comorbidities (e.g., hypertension, renal insufficiency), use of antiplatelet or anticoagulant, risk for trauma or corticosteroid intolerance (Provan *et al*, [2010](#bjh16161-bib-0032){ref-type="ref"}; Neunert *et al*, [2011](#bjh16161-bib-0029){ref-type="ref"}; Lu *et al*, [2014](#bjh16161-bib-0027){ref-type="ref"}). Several second‐line treatments were used, including immunosuppressive agents (i.e., azathioprine, danazol, ciclosporin, cyclophosphamide, vincristine, vinblastine, mycophenolate mofetil and dapsone), monoclonal antibodies (i.e., rituximab), thrombopoietin receptor agonists (TPO‐RAs, i.e., eltrombopag and romiplostim), or combinations thereof, which aim to improve the platelet count to ≥20--30 × 10^9^/l without bleeding symptoms (Provan *et al*, [2010](#bjh16161-bib-0032){ref-type="ref"}; Neunert *et al*, [2011](#bjh16161-bib-0029){ref-type="ref"}; Toltl & Arnold, [2011](#bjh16161-bib-0037){ref-type="ref"}; Moulis *et al*, [2014](#bjh16161-bib-0028){ref-type="ref"}). These treatments are appropriate for patients with significant bleeding, platelet count \<10--20 × 10^9^/l, or platelet count 20--30 × 10^9^/l after first‐line treatment (Provan *et al*, [2010](#bjh16161-bib-0032){ref-type="ref"}; Lu *et al*, [2014](#bjh16161-bib-0027){ref-type="ref"}). Physicians tend to select a second‐line therapy based on their experience (Stasi & Provan, [2004](#bjh16161-bib-0035){ref-type="ref"}), whereas splenectomy is reducing worldwide due to the effectiveness of medical treatment (Palandri *et al*, [2016](#bjh16161-bib-0030){ref-type="ref"}). Therefore, this review focuses on the efficacy of second‐line medical treatments for ITP.

Eight meta‐analyses assessed second‐line medical therapy in paediatric and adult patients with newly diagnosed, relapsed and persistent ITP (Cooper *et al*, [2012](#bjh16161-bib-0014){ref-type="ref"}; Chugh *et al*, [2015](#bjh16161-bib-0011){ref-type="ref"}; Feng *et al*, [2016](#bjh16161-bib-0017){ref-type="ref"}; Wang *et al*, [2016](#bjh16161-bib-0041){ref-type="ref"}; Elgebaly *et al*, [2017](#bjh16161-bib-0016){ref-type="ref"}; Arai *et al*, [2018](#bjh16161-bib-0001){ref-type="ref"}; Zhang *et al*, [2018](#bjh16161-bib-0043){ref-type="ref"}; Bylsma *et al*, [2019](#bjh16161-bib-0008){ref-type="ref"}). Among them, 4 (Cooper *et al*, [2012](#bjh16161-bib-0014){ref-type="ref"}; Wang *et al*, [2016](#bjh16161-bib-0041){ref-type="ref"}; Elgebaly *et al*, [2017](#bjh16161-bib-0016){ref-type="ref"}; Zhang *et al*, [2018](#bjh16161-bib-0043){ref-type="ref"}), 2 (Chugh *et al*, [2015](#bjh16161-bib-0011){ref-type="ref"}; Feng *et al*, [2016](#bjh16161-bib-0017){ref-type="ref"}) and 2 (Arai *et al*, [2018](#bjh16161-bib-0001){ref-type="ref"}; Bylsma *et al*, [2019](#bjh16161-bib-0008){ref-type="ref"}) meta‐analyses assessed efficacy of TPO‐RAs, monoclonal antibody and both, respectively. For the TPO‐RAs, 2 meta‐analyses (Wang *et al*, [2016](#bjh16161-bib-0041){ref-type="ref"}; Elgebaly *et al*, [2017](#bjh16161-bib-0016){ref-type="ref"}) combined paediatric and adult ITP patients, 1 (Wang *et al*, [2016](#bjh16161-bib-0041){ref-type="ref"}) combined randomised controlled trials (RCTs) with observational studies, and the rest (Cooper *et al*, [2012](#bjh16161-bib-0014){ref-type="ref"}; Elgebaly *et al*, [2017](#bjh16161-bib-0016){ref-type="ref"}; Arai *et al*, [2018](#bjh16161-bib-0001){ref-type="ref"}; Zhang *et al*, [2018](#bjh16161-bib-0043){ref-type="ref"}; Bylsma *et al*, [2019](#bjh16161-bib-0008){ref-type="ref"}) considered only RCTs. Three of them directly pooled the effects of eltrombopag and romiplostim individually or combined them as TPO‐RAs (Wang *et al*, [2016](#bjh16161-bib-0041){ref-type="ref"}; Elgebaly *et al*, [2017](#bjh16161-bib-0016){ref-type="ref"}; Bylsma *et al*, [2019](#bjh16161-bib-0008){ref-type="ref"}), while 3 (Cooper *et al*, [2012](#bjh16161-bib-0014){ref-type="ref"}; Arai *et al*, [2018](#bjh16161-bib-0001){ref-type="ref"}; Zhang *et al*, [2018](#bjh16161-bib-0043){ref-type="ref"}) indirectly pooled the effects of romiplostim relative to eltrombopag. For the 2 direct meta‐analyses on monoclonal antibody, 5 (Chugh *et al*, [2015](#bjh16161-bib-0011){ref-type="ref"}) and 7 (Feng *et al*, [2016](#bjh16161-bib-0017){ref-type="ref"}) RCTs comparing rituximab with placebo or standard treatments were pooled. The most recent network meta‐analysis (NMA) compared the efficacy across different types of second‐line drugs (Arai *et al*, [2018](#bjh16161-bib-0001){ref-type="ref"}). However, platelet count as a quantitative outcome was not considered, and risk‐benefit analysis was not carried out. Therefore, this systematic review and NMA was conducted to estimate the relative treatment efficacy (i.e., on platelet response, platelet count and bleeding) and safety (i.e., on adverse events) of the second‐line treatments (i.e., immunosuppressive agents, monoclonal antibodies and TPO‐RAs) for adult persistent ITP patients. The probability of being the best treatment with highest efficacy and lowest serious adverse events (SAE) was also estimated. Risk and benefit were then considered simultaneously.

Methods {#bjh16161-sec-0002}
=======

This study was performed following the Preferred Reports of Systematic Review and Meta‐Analysis (PRISMA) guideline (Hutton, [2015](#bjh16161-bib-0023){ref-type="ref"}), and was registered in PROSPERO (CRD42016044038).

Study identification {#bjh16161-sec-0003}
--------------------

Studies were identified from MEDLINE (via PubMed) and Scopus databases. The search was performed up to 21 September 2018. Search strategies are described in Tables [SI](#bjh16161-sup-0001){ref-type="supplementary-material"} and [SII](#bjh16161-sup-0001){ref-type="supplementary-material"}.

Eligibility criteria {#bjh16161-sec-0004}
--------------------

Only RCTs that included the following criteria were analysed: adult persistent ITP patients (failing initial treatment within 3--12 months or longer), compared a second‐line drug with placebo or another second‐line drug, reported any of following outcomes: platelet response, platelet count, bleeding and SAEs. Studies were excluded if they had insufficient data and no response after 3 attempts of contacting authors.

Treatments {#bjh16161-sec-0005}
----------

The second‐line treatments for persistent ITP included TPO‐RA monotherapy (i.e., recombinant human thrombopoietin (rhTPO), eltrombopag and romiplostim), monoclonal antibody (rituximab), immunosuppressive agents (i.e., azathioprine, ciclosporin, cyclophosphamide, danazol, dapsone, mycophenolate mofetil, vincristine and vinblastine), or combination(s) of the aforementioned monotherapies.

Outcomes of interest {#bjh16161-sec-0006}
--------------------

The primary outcome of interest was platelet response, i.e., achievement of platelet count ≥30 × 10^9^/l or ≥50 × 10^9^/l, as originally defined by each study, at 4--6 weeks after receiving second‐line treatment. The 3 secondary outcomes were quantitative platelet count at 6 weeks after treatment, any bleeding and composite SAEs, including death, thrombosis (i.e., occurrence of arterial/venous occlusion), and serious infection (i.e., grade 3--4) (<https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf>). Frequency of the most common event among them was used as the composite SAE data for studies reporting individual SAE but not the composite.

Study selection and data extraction {#bjh16161-sec-0007}
-----------------------------------

Two reviewers independently selected studies by screening titles and abstracts, and retrieved the full articles if a decision could not be made. Selection results were then validated; any disagreements were resolved by senior authors.

Data extraction was performed independently by 2 reviewers. Study characteristics were extracted, including country, study design, period of study, treatment regimens, baseline platelet count, cut‐off for platelet response, treatment duration, mean age, sex and percent splenectomy. In addition, data for pooling were extracted, including total number of subjects, any bleeding events, composite SAE, risk ratio (RR) with 95% confidence interval (CI) and mean with standard deviation of continuous outcomes.

Risk of bias assessment {#bjh16161-sec-0008}
-----------------------

The quality of studies was independently assessed by 2 reviewers. Disagreement was resolved by a senior author. The risk of bias was assessed using the Cochrane Collaboration's tool for RCTs (Higgins *et al*, [2011](#bjh16161-bib-0021){ref-type="ref"}). Each item was graded as "low risk" or "high risk"; if there was insufficient information to judge, it was classified as "unclear".

Statistical analysis {#bjh16161-sec-0009}
--------------------

Direct meta‐analysis (DMA) was performed on 3 dichotomous outcomes (i.e., platelet response, any bleeding, and composite SAEs) and 1 quantitative platelet count outcome. Relative treatment effects were estimated for these corresponding outcomes using RRs and un‐standardised mean difference (USMD). Heterogeneity was assessed using *Q* test and *I* ^2^ statistic (Thompson & Sharp, [1999](#bjh16161-bib-0036){ref-type="ref"}; Petitti, [2001](#bjh16161-bib-0031){ref-type="ref"}). The sources of heterogeneity were explored by fitting each study characteristic in a meta‐regression model. A characteristic was considered a source of heterogeneity if the *I* ^2^ decreased following its inclusion in the model. A subgroup analysis was then performed accordingly.

NMA with consistency model was applied to assess relative treatment effects between different second‐line drugs, which were coded as 1--9 for placebo, eltrombopag, romiplostim, rituximab, danazol, rhTPO, rhTPO+danazol, rhTPO+ciclosporin and rhTPO+rituximab, respectively. Indirect comparisons between active treatments were performed by borrowing information from a common comparator (i.e., placebo).

Treatments were ranked using rankogram and surface under the cumulative ranking curve (SUCRA). The consistency assumption was assessed using a design‐by‐treatment interaction model (Higgins *et al*, [2012](#bjh16161-bib-0022){ref-type="ref"}; Jackson *et al*, [2016](#bjh16161-bib-0024){ref-type="ref"}). Publication bias was assessed by comparison‐adjusted funnel plot (Chaimani *et al*, [2013](#bjh16161-bib-0009){ref-type="ref"}). Finally, clustered ranking plot for 2 outcomes was constructed according to the treatments' SUCRA values to demonstrate their ranks simultaneously in terms of both benefit and risk. All analyses were performed using Stata version 15.1 (StataCorp LLC, College Station, TX, USA).

Role of the funding source {#bjh16161-sec-0010}
--------------------------

This study has no funding source. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.

Results {#bjh16161-sec-0011}
=======

A total of 116 and 1670 studies were identified from MEDLINE and Scopus, respectively. Eighty‐nine duplicates were removed, leaving 1697 studies to be screened on titles and abstracts. Fourteen studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) were finally eligible (Fig [1](#bjh16161-fig-0001){ref-type="fig"}).

![Flow chart of study selection. RCT, randomised controlled trial; SAE, serious adverse event.](BJH-188-450-g001){#bjh16161-fig-0001}

The characteristics of these 14 studies are described in Table [1](#bjh16161-tbl-0001){ref-type="table"}. All studies were RCTs and mainly multi‐centre, except for one (Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}), with sample sizes ranging from 21 to 234. All studies were two‐arm comparisons, including 5 studies (Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) for eltrombopag *versus* placebo, 4 (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}) for romiplostim *versus* placebo, 2 (Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}) for rituximab *versus* placebo, 1 (Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}) for rhTPO+ciclosporin *versus* rhTPO, 1 (Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}) for rhTPO+rituximab *versus* rituximab and 1 (Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}) for rhTPO+danazol *versus* danazol. Nine RCTs (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) included exclusively patients with persistent ITP, while 4 (Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}) included mixed newly diagnosed and persistent ITP patients and 1 (Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}) did not mention ITP phase. Median age ranged from 34 to 59 years and the percentage of females ranged from 56% to 75%. Median platelet count at baseline ranged from 10 × 10^9^/l to 29 × 10^9^/l. Platelet response was defined as platelet ≥50 × 10^9^/l in 11 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}), and ≥30 × 10^9^/l in 3 studies (Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}). The treatment duration ranged from 2 to 52 weeks (median = 6 weeks), while the follow‐up period ranged from 4 to 78 weeks (median = 24 weeks). One (Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}) and 11 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) reported platelet response at 4 and 6 weeks, respectively. Only 2 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}) of romiplostim *versus* placebo reported baseline thrombopoietin level. History of having received 3 or more treatment regimens was reported in 5 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}). Corticosteroids were the most common previous treatment followed by intravenous immunoglobulin. Percentage of splenectomy was reported in 10 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) ranging from 10·4% to 69·6%, with a median time after splenectomy of 6·6--8·1 years.

###### 

Characteristics of included studies.

  Author, year                                                    Country                   Treatments                           Median platelet count (×10^9^/l)   Platelet response (×10^9^/l)   Duration of treatment (weeks)   Duration of follow‐up (weeks)   Median age (years)   \% Female   \% Splenectomy
  --------------------------------------------------------------- ------------------------- ------------------------------------ ---------------------------------- ------------------------------ ------------------------------- ------------------------------- -------------------- ----------- ----------------
  Bussel *et al*([2006](#bjh16161-bib-0004){ref-type="ref"})      USA                       Romiplostim *versus* placebo         16                                 Platelet count ≥50             6                               12                              49                   71·4        67
  Bussel *et al*([2007](#bjh16161-bib-0005){ref-type="ref"})      USA                       Eltrombopag *versus* placebo         16                                 Platelet count ≥50             6                               12                              50                   62          47
  Kuter *et al*([2008](#bjh16161-bib-0025){ref-type="ref"})       Europe, USA               Romiplostim *versus* placebo         16                                 Platelet count ≥50             24                              36                              52                   65          50·4
  Bussel *et al*([2009](#bjh16161-bib-0006){ref-type="ref"})      23 countries              Eltrombopag *versus* placebo         19·7                               Platelet count ≥50             6                               12                              48                   61          39
  Kuter *et al*([2010](#bjh16161-bib-0026){ref-type="ref"})       Australia, Europe, USA    Romiplostim *versus* placebo         29                                 Platelet count \>50            52                              78                              57                   56          --
  Cheng *et al*([2011](#bjh16161-bib-0010){ref-type="ref"})       23 countries              Eltrombopag *versus* placebo         16                                 Platelet count ≥50             24                              24                              48·7                 69          36
  Shirasugi *et al*([2011](#bjh16161-bib-0034){ref-type="ref"})   Japan                     Romiplostim *versus* placebo         17·5                               Platelet count ≥50             12                              24                              58·3                 70·6        44
  Arnold *et al*([2012](#bjh16161-bib-0002){ref-type="ref"})      Canada                    Rituximab *versus* placebo           14·6                               Platelet count ≥50             4                               26                              40                   58·3        --
  Tomiyama *et al*([2012](#bjh16161-bib-0038){ref-type="ref"})    Japan                     Eltrombopag *versus* placebo         17                                 Platelet count ≥50             6                               26                              58·9                 65·2        69·6
  Wang *et al*([2012](#bjh16161-bib-0040){ref-type="ref"})        China                     rhTPO+danazol *versus* danazol       10·4                               Platelet count ≥50             2                               4                               40·8                 63·2        12·5
  Cui *et al*([2013](#bjh16161-bib-0015){ref-type="ref"})         China                     rhTPO+ciclosporin *versus* rhTPO     11·9                               Platelet count ≥30             2                               12                              33·9                 55·6        --
  Ghanima *et al*([2015](#bjh16161-bib-0019){ref-type="ref"})     France, Norway, Tunisia   Rituximab *versus* placebo           18·5                               Platelet count ≥30             4                               78                              46                   72·5        --
  Zhou *et al*([2015](#bjh16161-bib-0044){ref-type="ref"})        China                     Rituximab+rhTPO *versus* rituximab   10·2                               Platelet count ≥30             4                               26                              42·2                 65·2        10·4
  Yang *et al*([2017](#bjh16161-bib-0042){ref-type="ref"})        China                     Eltrombopag *versus* placebo         13·75                              Platelet count ≥50             8                               6                               45                   75·4        16·1

rhTPO, recombinant human thrombopoietin.
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Ten studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) reported the percentage of concurrent treatments, which ranged from 11% to 83%. For eltrombopag *versus* placebo, dosage of eltrombopag was 12·5--50 mg/day for 24 weeks (Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}), 25--75 mg/day for 8 weeks (Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}), 30--75 mg/day for 6 weeks (Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}), 50--75 mg/day for 6 weeks (Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}) and 24 weeks (Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}). For romiplostim *versus* placebo, dosage of romiplostim was 1--2 µg/kg subcutaneously (SC) once a week for 24 weeks (Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}), 1--6 µg/kg SC once a week for 6 weeks (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}) and 3--10 µg/kg SC once a week for 52 weeks (Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}) and 12 weeks (Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}). For rituximab *versus* placebo, dosage of rituximab for patients in both studies (Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Ghanima *et al*, [2012](#bjh16161-bib-0018){ref-type="ref"}) was 375 mg/m^2^ intravenously once a week for 4 weeks. For rhTPO studies, dosage of rhTPO was 1 µg/kg SC once daily for 2 weeks (Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}).

The results of risk of bias assessment are described in Table [SIII](#bjh16161-sup-0001){ref-type="supplementary-material"}. Most items were assessed as unclear because of insufficient information including random sequence generation (57·1%), allocation concealment (57·1%), blinding (85·7%) and other sources of bias (57·1%). However, all studies were judged low risk for selective outcome reporting.

The results of DMA are reported in Tables [SIV--SVII](#bjh16161-sup-0001){ref-type="supplementary-material"} and Figures [S1--S4](#bjh16161-sup-0001){ref-type="supplementary-material"}. For platelet response, eltrombopag and romiplostim resulted in a 3·99 (2·54, 6·26) and 4·82 (1·77, 13·12) times higher response than placebo, respectively. In addition, these corresponding treatments and rituximab also resulted in significantly higher platelet counts than placebo with USMDs of 51·06 (32·85, 69·26) and 82·68 (45·21, 123·81) and 22·05 (4·42, 39·67) ×10^9^/l, respectively. Risk of bleeding was lower for all treatments but only eltrombopag was significant \[RR = 0·82 (0·74, 0·91)\]. Meanwhile, romiplostim had significantly lower risk for SAEs than placebo \[RR = 0·39 (0·17, 0·93)\] but eltrombopag did not \[RR = 1·17 (0·35, 3·92)\].

Heterogeneity was moderate to high except for rituximab *versus* placebo on platelet response, rituximab *versus* placebo on platelet counts, eltrombopag and rituximab *versus* placebo on any bleeding and eltrombopag and romiplostim *versus* placebo on SAEs. Sources of heterogeneity (study and patient characteristics) were explored, but none were found.

The results of NMA are detailed as follows. Fourteen studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) reported platelet response as an outcome. Two studies (Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}) comparing rhTPO+danazol *versus* danazol and rhTPO+ciclosporin *versus* rhTPO were disconnected from other comparisons, and were therefore excluded from the network. A network map was constructed for 12 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) (1313 subjects) consisting of 4 direct comparisons among 5 treatments (Fig [2](#bjh16161-fig-0002){ref-type="fig"}A). Among them, 11 studies (Bussel *et al*, [2006](#bjh16161-bib-0004){ref-type="ref"}; Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Yang *et al*, [2017](#bjh16161-bib-0042){ref-type="ref"}) used a platelet cut‐off of 50 × 10^9^/l, but 1 study (Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}) used a platelet cut‐off of 30 × 10^9^/l. For all relative treatment comparisons (Table [2](#bjh16161-tbl-0002){ref-type="table"}, above diagonal line), eltrombopag and romiplostin provided the most effective outcomes compared with placebo, with the former having a slight (non‐significant) advantage in terms of platelet response \[RR = 1·10 (0·46, 2·67)\]. Both eltrombopag and romiplostim were significantly more effective than rituximab and rhTPO+rituximab with corresponding pooled RRs of 4·56 (1·89, 10·96) and 4·18 (1·21, 14·49) for eltrombopag; 4·13 (1·56, 10·94) and 3·79 (1·02, 14·09) for romiplostim. Eltrombopag was ranked as the best treatment for platelet response according to its SUCRA of 89·6, followed by romiplostim, rhTPO+rituximab, placebo and rituximab, respectively (Table [3](#bjh16161-tbl-0003){ref-type="table"}). There was no evidence of inconsistency effects (global χ^2^ = 0·04, *P* = 0·850) or publication bias for platelet response (Figure [S5](#bjh16161-sup-0001){ref-type="supplementary-material"}A).

![Network map for all outcomes. (A) Platelet response. (B) Platelet count. (C) Any bleeding. (D) Composite serious adverse events. The number of studies and patients, indicated above each line, are depicted by the size of nodes and line thickness, respectively. Ritu, rituximab; rhTPO, recombinant human thrombopoietin. \[Colour figure can be viewed at <http://www.wileyonlinelibrary.com>\]](BJH-188-450-g002){#bjh16161-fig-0002}

###### 

All possible pairwise comparisons of treatments for persistent ITP on platelet response and platelet count: a network meta‐analysis.

                           Platelet response                                                                               
  ------------------------ ------------------------ ------------------------ ------------------------ -------------------- -------------------
  Platelet count           Eltrombopag              1·10 (0·46, 2·67)        4·56 (1·89, 10·96)       4·18 (1·21, 14·49)   4·32 (2·36, 7·88)
  −27·86 (−68·48, 12·75)   Romiplostim              4·13 (1·56, 10·94)       3·79 (1·02, 14·09)       3·91 (1·88, 8·16)    
  26·93 (−24·21, 78·06)    54·79 (0·12, 109·46)     Rituximab                0·92 (0·38, 2·21)        0·95 (0·50, 1·79)    
  4·69 (−68·65, 78·03)     32·55 (−43·30, 108·40)   −22·24 (−74·82, 30·35)   rhTPO+rituximab          1·03 (0·35, 3·05)    
  53·79 (28·27, 79·32)     81·66 (49·63, 113·69)    26·87 (−17·67, 71·40)    49·11 (−19·80, 118·01)   Placebo              

Results are risk ratios (95% confidence intervals \[CIs\]) for platelet response and un‐standardised mean difference (95% CIs) for platelet count between each pair of treatments from network meta‐analysis. Comparisons are read from left to right. rhTPO, recombinant human thrombopoietin.

John Wiley & Sons, Ltd

###### 

The surface under the cumulative ranking curve and rank of each treatment for platelet response, platelet count, any bleeding and composite serious adverse events outcomes.

  Treatment         Platelet response   Platelet count   Any bleeding   Composite serious adverse events                      
  ----------------- ------------------- ---------------- -------------- ---------------------------------- ------ ---- ------ ---
  Placebo           26·2                4                5·1            5                                  92·7   1    48·3   4
  Eltrombopag       89·6                1                62·8           2                                  32·8   3    51·4   3
  Romiplostim       84·5                2                92·8           1                                  42·2   2    8·1    5
  Rituximab         20·8                5                32·8           4                                  32·3   4    62·6   2
  rhTPO+rituximab   28·8                3                56·5           3                                  --     --   79·6   1

rhTPO, recombinant human thrombopoietin; SUCRA, surface under the cumulative ranking curve.

John Wiley & Sons, Ltd

Twelve studies (Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Wang *et al*, [2012](#bjh16161-bib-0040){ref-type="ref"}; Cui *et al*, [2013](#bjh16161-bib-0015){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}) reported platelet count as an outcome with 1301 subjects, which included 4 direct comparisons among 5 treatments (Fig [2](#bjh16161-fig-0002){ref-type="fig"}B). All possible pairwise comparisons were made (Table [2](#bjh16161-tbl-0002){ref-type="table"}, below diagonal line), indicating that romiplostim produced the most effective platelet count compared to placebo, followed by eltrombopag, rhTPO+rituximab and rituximab with pooled USMD of 81·66 × 10^9^/l (49·63, 113·69), 53·79 × 10^9^/l (28·27, 79·32), 49·11 × 10^9^/l (−19·80, 118·01) and 26·87 × 10^9^/l (−17·67, 71·40), respectively. In 6 comparisons, none of the active drugs were statistically significantly associated with platelet count outcome. Romiplostim ranked as the best treatment for platelet count (SUCRA = 92·8), followed by eltrombopag, rhTPO+rituximab, and rituximab, respectively (Table [3](#bjh16161-tbl-0003){ref-type="table"}). There was no evidence of inconsistency effects (global χ^2^ = 0·69, *P* = 0·407). There was evidence of publication bias for platelet count (Figure [S5](#bjh16161-sup-0001){ref-type="supplementary-material"}B).

Nine studies (Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}) reported any bleeding outcome. Data from these 9 studies (1042 subjects) included 3 direct comparisons among 4 treatments (Fig [2](#bjh16161-fig-0002){ref-type="fig"}C). All possible pairwise comparisons were made, which indicated that rituximab had the lowest risk for any bleeding when compared to placebo, followed by eltrombopag and romiplostim, with pooled RR of 0·76 (0·49, 1·18), 0·79 (0·65, 0·96) and 0·82 (0·59, 1·13), respectively. However, all placebo and active controlled comparisons were not statistically significant, except eltrombopag *versus* placebo (Table [4](#bjh16161-tbl-0004){ref-type="table"}, above diagonal line). The highest probability of bleeding was found in placebo, followed by romiplostim, eltrombopag, and rituximab, respectively (Table [3](#bjh16161-tbl-0003){ref-type="table"}). There was no evidence of inconsistency effects (global χ^2^ = 0·99, *P* = 0·319) or publication bias (Figure [S5](#bjh16161-sup-0001){ref-type="supplementary-material"}C).

###### 

All possible pairwise comparisons of treatments for persistent ITP on any bleeding and composite serious adverse events: network meta‐analysis.

                                     Any bleeding                                                                       
  ---------------------------------- ------------------- -------------------- --------------------- ------------------- -------------------
  Composite serious adverse events   Eltrombopag         0·97 (0·69, 1·35)    1·04 (0·64, 1·68)     --                  0·79 (0·65, 0·96)
  2·77 (0·65, 11·71)                 Romiplostim         1·07 (0·61, 1·86)    --                    0·82 (0·59, 1·13)   
  0·58 (0·04, 8·15)                  0·21 (0·02, 2·63)   Rituximab            --                    0·76 (0·49, 1·18)   
  0·24 (0·00, 13·11)                 0·09 (0·00, 4·40)   0·41 (0·02, 8·34)    rhTPO+rituximab       --                  
  1·09 (0·34, 3·45)                  0·39 (0·17, 0·93)   1·86 (0·17, 19·95)   4·54 (0·10, 210·26)   Placebo             

Results are risk ratios (95% confidence intervals) between each pair of treatments from network meta‐analysis. Comparisons are read from left to right. rhTPO, recombinant human thrombopoietin.

John Wiley & Sons, Ltd

Eleven studies (Bussel *et al*, [2007](#bjh16161-bib-0005){ref-type="ref"}; Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Bussel *et al*, [2009](#bjh16161-bib-0006){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Cheng *et al*, [2011](#bjh16161-bib-0010){ref-type="ref"}; Shirasugi *et al*, [2011](#bjh16161-bib-0034){ref-type="ref"}; Tomiyama *et al*, [2012](#bjh16161-bib-0038){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}; Zhou *et al*, [2015](#bjh16161-bib-0044){ref-type="ref"}) reporting composite SAE outcome were included in the network with 1253 total subjects. These consisted of 4 direct comparisons among 5 treatments (Fig [2](#bjh16161-fig-0002){ref-type="fig"}D). All possible pairwise comparisons were made (Table [4](#bjh16161-tbl-0004){ref-type="table"}, below diagonal line), and rhTPO+rituximab had the highest risk of composite SAEs when compared to placebo followed by rituximab and eltrombopag with pooled RR of 4·54 (0·10, 210·26), 1·86 (0·17, 19·95) and 1·09 (0·34, 3·45), respectively. Romiplostim had the lowest composite SAEs when compared to placebo with a statistically significant pooled RR of 0·39 (0·17, 0·93). In addition, the latter 3 active treatments had non‐significantly lower risk for composite SAEs than rhTPO+rituximab, with pooled RRs of 0·41 (0·02, 8·34), 0·24 (0·00, 13·11) and 0·09 (0·00, 4·40), respectively. The treatment with greatest probability for highest SAEs was rhTPO+rituximab, followed by rituximab, eltrombopag, placebo and romiplostim, respectively (Table [3](#bjh16161-tbl-0003){ref-type="table"}). There was no evidence of inconsistency effects (global χ^2^ = 0·34, *P* = 0·562) or publication bias (Figure [S5](#bjh16161-sup-0001){ref-type="supplementary-material"}D).

A clustered ranking plot was constructed between SAEs on *x*‐axis and the other 3 outcomes (i.e., platelet response, platelet count, and any bleeding) on *y*‐axis (Fig [3](#bjh16161-fig-0003){ref-type="fig"}). Romiplostim ranked highest for platelet count (with highest SUCRA) and SAEs (with lowest SUCRA). It ranked second for platelet response with a SUCRA slightly lower than eltrombopag, which seemed most efficacious in this outcome but had higher risk for SAEs than romiplostim and placebo. The rhTPO+rituximab combination and rituximab carried the greatest risk of SAEs, although the latter had the smallest risk of bleeding.

![Clustered ranking plot of surface under the cumulative ranking curve (SUCRA) for composite serious adverse events *versus* platelet response, platelet count and any bleeding. \[Colour figure can be viewed at <http://www.wileyonlinelibrary.com>\]](BJH-188-450-g003){#bjh16161-fig-0003}

Discussion {#bjh16161-sec-0012}
==========

Our NMA included 12 RCTs evaluating both short‐term efficacy and adverse events of second‐line medical treatment for persistent ITP in adults. The overall results from NMA were consistent and indicated that romiplostim and eltrombopag had significantly higher efficacy in terms of platelet response and platelet count when compared with placebo. In addition, both treatments were also more efficacious than rituximab monotherapy or rhTPO+rituximab combination. Considering clinical efficacy and adverse events simultaneously using clustered ranking indicated that the treatment with the best balance between high short‐term efficacy with regard to platelet response, platelet count low risk of bleeding and adverse events was romiplostim, followed by eltrombopag. Rituximab had the lowest clinical efficacy and highest risk for SAEs.

The results of this study are compatible with the mechanism of action of TPO‐RAs and rituximab in ITP. Romiplostim is a peptide TPO‐RA which binds to the extracellular domain of thrombopoietin receptor, activates JAK‐STAT, MAPK and PI3K‐AKT pathways, stimulates proliferation and maturation of megakaryocytes, and inhibits apoptosis of megakaryocytes; resulting in increased platelet production (Vishnu & Aboulafia, [2016](#bjh16161-bib-0039){ref-type="ref"}; Cooper, [2017](#bjh16161-bib-0012){ref-type="ref"}). Eltrombopag is a non‐peptide TPO‐RA that binds to the transmembrane domain of thrombopoietin receptor and activates the same pathways as romiplostim (Cooper, [2017](#bjh16161-bib-0012){ref-type="ref"}; Gonzalez‐Porras & Bastida, [2018](#bjh16161-bib-0020){ref-type="ref"}). Being less specific to ITP than the TPO‐RAs, rituximab is a monoclonal antibody which binds to the surface of CD20‐positive B lymphocytes and induces B‐cell depletion (Braendstrup *et al*, [2005](#bjh16161-bib-0003){ref-type="ref"}).

Our study was considerably similar to the recent NMA by Arai *et al*([2018](#bjh16161-bib-0001){ref-type="ref"}), which was published whilst our manuscript was in submission. Although the total number of RCTs meeting their inclusion criteria were different from ours (i.e., 24 *Versus* 14 RCTs), the number of RCTs included in the pooling of primary outcome of platelet response was the same (i.e., 12 RCTs). Among them, 1 study of a new TPO‐RA (i.e., avatrombopag) *versus* placebo (Bussel *et al*, [2014](#bjh16161-bib-0007){ref-type="ref"}) was included in their NMA but not in ours because it was a phase II RCT; whereas another study of rituximab *versus* placebo (Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}) was included in our NMA but not in theirs. Their outcomes of interest were mostly similar to ours except they considered early response within 1--2 weeks, rescue treatments, and quality of life, with small number of RCTs for each, and could not perform NMA. For platelet response, their NMA indicated that eltrombopag had the first rank, similar to ours. For the bleeding outcome, the ranking was considerably different: TPO‐RAs (i.e., eltrombopag and romiplostim) ranked first and second in lowering bleeding while rituximab was the first in our study. This was probably because a different endpoint for bleeding was used (i.e., clinically significant bleeding *versus* any bleeding in our study). However, the quantitative platelet count was not considered in their review, nor were the efficacy and safety evaluated simultaneously.

Our study has a number of strengths. The results of NMA can demonstrate relative treatment effects between any pair of active treatments and their ranking as best/worst treatments. Risk (i.e., SAEs) and benefit (i.e., efficacy) are also considered simultaneously using clustered ranking plot. Romiplostim and eltrombopag have significantly higher efficacy and lower adverse events than rituximab, with romiplostin having a safer adverse event profile than eltrombopag; this provides a comprehensive summary of these treatment options. Our study has some limitations that should be considered. First, the number of relevant studies and most of their sample sizes were small. Second, variations in drug dosage and protocol may cause heterogeneity and affect the clinical outcomes. Working on summary data does not allow us to re‐categorise treatment regimens or adjust for differences like individual patient data meta‐analysis does, but the latter is time‐consuming and requires willingness to share data. Third, the clinical outcomes evaluated in the included studies were only short‐term; these treatments might possibly give different results in the long term. Lastly, we focused on treatments for persistent ITP, but 4 RCTs (Kuter *et al*, [2008](#bjh16161-bib-0025){ref-type="ref"}; Kuter *et al*, [2010](#bjh16161-bib-0026){ref-type="ref"}; Arnold *et al*, [2012](#bjh16161-bib-0002){ref-type="ref"}; Ghanima *et al*, [2015](#bjh16161-bib-0019){ref-type="ref"}) had mixed acute and persistent ITP patients with median disease duration of 0·5--7·4 years.

In conclusion, this systematic review and NMA indicates that romiplostim and eltrombopag have high efficacy and safety as second‐line treatments in the short term for adult patients with persistent ITP. Rituximab may not be beneficial due to lower efficacy and higher complications compared with TPO‐RAs. Further evaluation of long‐term outcomes, as well as cost‐effectiveness and impact analyses for both TPO‐RAs should be performed to guide health‐care policy makers.
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